Serum proteomic patterns for detection of prostate cancer - PubMed Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2002 Oct 16;94(20):1576-8.
doi: 10.1093/jnci/94.20.1576.

Serum proteomic patterns for detection of prostate cancer

Emanuel F Petricoin 3rd  1 , David K Ornstein, Cloud P Paweletz, Ali Ardekani, Paul S Hackett, Ben A Hitt, Alfredo Velassco, Christian Trucco, Laura Wiegand, Kamillah Wood, Charles B Simone, Peter J Levine, W Marston Linehan, Michael R Emmert-Buck, Seth M Steinberg, Elise C Kohn, Lance A Liotta
Affiliations

Serum proteomic patterns for detection of prostate cancer

Emanuel F Petricoin 3rd et al. J Natl Cancer Inst. .

Abstract

Pathologic states within the prostate may be reflected by changes in serum proteomic patterns. To test this hypothesis, we analyzed serum proteomic mass spectra with a bioinformatics tool to reveal the most fit pattern that discriminated the training set of sera of men with a histopathologic diagnosis of prostate cancer (serum prostate-specific antigen [PSA] > or =4 ng/mL) from those men without prostate cancer (serum PSA level <1 ng/mL). Mass spectra of blinded sera (N = 266) from a test set derived from men with prostate cancer or men without prostate cancer were matched against the discriminating pattern revealed by the training set. A predicted diagnosis of benign disease or cancer was rendered based on similarity to the discriminating pattern discovered from the training set. The proteomic pattern correctly predicted 36 (95%, 95% confidence interval [CI] = 82% to 99%) of 38 patients with prostate cancer, while 177 (78%, 95% CI = 72% to 83%) of 228 patients were correctly classified as having benign conditions. For men with marginally elevated PSA levels (4-10 ng/mL; n = 137), the specificity was 71%. If validated in future series, serum proteomic pattern diagnostics may be of value in deciding whether to perform a biopsy on a man with an elevated PSA level.

PubMed Disclaimer

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles